These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
416 related items for PubMed ID: 14639383
1. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. J Am Acad Dermatol; 2003 Dec; 49(6):1049-58. PubMed ID: 14639383 [Abstract] [Full Text] [Related]
2. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders. Yamaguchi T, Ohshima K, Karube K, Kawano R, Nakayama J, Suzumiya J, Kikuchi M. Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894 [Abstract] [Full Text] [Related]
3. CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. Paulli M, Berti E, Rosso R, Boveri E, Kindl S, Klersy C, Lazzarino M, Borroni G, Menestrina F, Santucci M. J Clin Oncol; 1995 Jun; 13(6):1343-54. PubMed ID: 7751878 [Abstract] [Full Text] [Related]
4. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review. Di Raimondo C, Parekh V, Song JY, Rosen ST, Querfeld C, Zain J, Martinez XU, Abdulla FR. Curr Hematol Malig Rep; 2020 Aug; 15(4):333-342. PubMed ID: 32435988 [Abstract] [Full Text] [Related]
5. CD30+ Lymphoproliferative Disorders of the Skin. Sauder MB, O'Malley JT, LeBoeuf NR. Hematol Oncol Clin North Am; 2017 Apr; 31(2):317-334. PubMed ID: 28340881 [Abstract] [Full Text] [Related]
7. SATB1 Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile. Sun J, Yi S, Qiu L, Fu W, Wang A, Liu F, Wang L, Wang T, Chen H, Wang L, Kadin ME, Tu P, Wang Y. J Invest Dermatol; 2018 Aug; 138(8):1795-1804. PubMed ID: 29510190 [Abstract] [Full Text] [Related]
8. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders? Collins K, Gu J, Aung PP, Nagarajan P, Curry JL, Huen A, Ivan D, Prieto VG, Tetzlaff MT, Duvic M, Miranda RN, Vega F, Torres-Cabala CA. Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757 [Abstract] [Full Text] [Related]
10. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. Wieser I, Oh CW, Talpur R, Duvic M. J Am Acad Dermatol; 2016 Jan; 74(1):59-67. PubMed ID: 26518172 [Abstract] [Full Text] [Related]
11. Spectrum of CD30 lymphoproliferative diseases from lymphomatoid papulosis to anaplastic large cell lymphoma. Louvet S, Dompmartin A, Troussard X, Galateau F, Moreau A, Reman O, Leporrier M, Leroy D. Int J Dermatol; 1996 Dec; 35(12):842-8. PubMed ID: 8970838 [No Abstract] [Full Text] [Related]
12. A comparison of clinical, morphological and immunohistochemical features of lymphomatoid papulosis and primary cutaneous CD30(Ki-1)-positive anaplastic large cell lymphoma. Tomaszewski MM, Lupton GP, Krishnan J, May DL. J Cutan Pathol; 1995 Aug; 22(4):310-8. PubMed ID: 7499570 [Abstract] [Full Text] [Related]
13. Comparison of CD163+ Macrophages and CD206+ Cells in Lesional Skin of CD30+ Lymphoproliferative Disorders of Lymphomatoid Papulosis and Primary Cutaneous Anaplastic Large-cell Lymphoma. Kakizaki A, Fujimura T, Kambayashi Y, Furudate S, Kawano M, Ogasawara K, Aiba S. Acta Derm Venereol; 2015 May; 95(5):600-2. PubMed ID: 25403560 [No Abstract] [Full Text] [Related]
14. Spectrum of CD30+ lymphoid proliferations in the eyelid lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma. Sanka RK, Eagle RC, Wojno TH, Neufeld KR, Grossniklaus HE. Ophthalmology; 2010 Feb; 117(2):343-51. PubMed ID: 19969358 [Abstract] [Full Text] [Related]
15. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders. Kempf W. Semin Diagn Pathol; 2017 Jan; 34(1):22-35. PubMed ID: 27993440 [Abstract] [Full Text] [Related]
16. Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy. Querfeld C, Kuzel TM, Guitart J, Rosen ST. Oncology (Williston Park); 2007 May; 21(6):689-96; discussion 699-700,. PubMed ID: 17564326 [Abstract] [Full Text] [Related]
18. Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma. Yagi H, Tokura Y, Furukawa F, Takigawa M. J Invest Dermatol; 1996 Dec; 107(6):827-32. PubMed ID: 8941669 [Abstract] [Full Text] [Related]
19. CD30+ lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma followed by lymphomatoid papulosis. Aoki M, Niimi Y, Takezaki S, Azuma A, Seike M, Kawana S. Br J Dermatol; 2001 Jul; 145(1):123-6. PubMed ID: 11453920 [Abstract] [Full Text] [Related]
20. Novel use of 308-nm excimer laser to treat a primary cutaneous CD30+ lymphoproliferative nodule. Meisenheimer JL. J Drugs Dermatol; 2007 Apr; 6(4):440-2. PubMed ID: 17668543 [Abstract] [Full Text] [Related] Page: [Next] [New Search]